Accelerating Medicines Partnership® Program Principles

A. Conflict of Interest

Individuals who serve on an AMP Project Steering Committee as either voting or non-voting members must disclose any potential conflicts of interest, whether real or perceived, to the Executive Secretary. Potential conflicts which develop during a member’s tenure on an AMP Project Steering Committee also must be disclosed. Any conflicts of interest that arise are to be documented and reviewed with FNIH and the AMP Executive Committee, who will jointly develop a mitigation strategy. Recusal of a member may be required when a conflict is identified and cannot be otherwise managed.

B. Confidentiality

It is a policy of the FNIH that sensitive and/or non-public information relating to the Project activities will only be discussed by persons and entities involved in the Project and, if necessary, under an appropriate confidential disclosure agreement. Project progress reports and other information are not considered confidential information unless labelled “confidential.”

C. Anti-trust

The Project participants agree that all research activities funded by the partnership fall into the pre-competitive space. There is to be no discussion of marketing activities. FNIH personnel will sit on all Project Steering Committee meetings to monitor this policy.

D. Solicitations

Solicitations will be open where practicable. Sole source solicitations are permissible but require justification. National Institutes of Health (NIH) solicitations must follow Federal law and regulations and NIH policy.

E. Publications

The Project will operate under a "team science" approach, and publications will have joint authorship. Specific publication strategies will be developed by an AMP Project Steering Committee prior to Project start, including proposal for lead authors and co-authors. All publications and data resources must acknowledge AMP project investigators and funder(s). Specific publication strategies will be discussed with the AMP Project Steering Committee.
F. Intellectual property (IP)

Given its precompetitive research focus and commitment to making results of that research available as broadly and promptly as possible, it is not expected that AMP projects will generate novel intellectual property (IP). AMP project research partners may use pre-existing IP of the other AMP project research partners for work done under the partnership. AMP project research partners agree not to file patent applications on research discoveries made under the partnership, except in the rare instance when a consensus of FNIH and the AMP Project Steering Committee agree that it is in the best interests of the partnership and public health to do so. IP developed under NIH awards are subject to applicable Federal law, regulation, and policies.